<u>Cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the</u> <u>feasibility of an audiological monitoring program</u>

INTERVIEW QUESTIONNAIRE FOR ONCOLOGY CLINIC PERSONNEL AND PHARMACISTS POST OTOTOXICITY PROGRAM

Dear Participant

We are delighted that you have agreed to participate and would like to thank you sincerely, for the information from this study can be used to help us understand the complexities associated with chemotherapy. The information that you provide will be treated with the strictest of confidence and please do not hesitate to ask us any questions that you may have during the course of the study. Contact details are reflected on the information and consent document.

INSTRUCTIONS

- 1. Please mark the appropriate answer to each question with an X, and give further detail if necessary.
- 2. Please answer all questions.

1. How many patient	ts with cervical	cancer did you	ı treat/dispe	nse cisplatin	medicatio	n to, durir
the study period?	< 20	20-49		50-69		70-100
2. Did you notice an	y changes in the	e patient's hear	ring?			
Yes		No			Sometimes	
3. Do you provide pa	tients with info	rmation regard	ling the otot	oxic effects	of medicat	ion?
Yes		No			Sometimes	
4. Do you provide pa	tients with any	information re	garding thei	r hearing?		
Yes		No			Sometimes	
5. Do you enquire ab	oout patient's hi		ng difficultie	es?	g .:	
Yes		No			Sometimes	
(II	1- 1	d. 4. 4b	.1	41 14	0	
6. How many referra	20-49	de to the audic	50-69	ine last year	70-100	
7. How many hours is	n a day are sper	nt on the ototox	xicity monit	oring progra	ım?	
< 2 hours	2- <4 ho	ours	4-<6 hours	S	6-8 hou	rs
B. Do you feel that the	ne ototoxicity n	nonitoring prog	gram is bene	ficial?		
Yes		No				
8.1. Why?						

Yes	No	Sometimes		
Tes	140	Sometimes		
3.2.1. Discuss				
3.2.2. Describe the collaboration	ration with the audiologist and other tean	n members.		
TH	ANK YOU FOR YOUR TIME AND CO	OPERATION		